The American Society of Hematology Elects New Leadership
October 04, 2012
Washington, D.C.-The American Society of Hematology (ASH), the world’s largest professional society concerned with the causes and treatment of blood disorders, today announced the election of four new members to its Executive Committee, the governing body of the organization, for terms to begin in January 2013.
David A. Williams, MD, will serve a one-year term as vice president, followed by successive terms as president-elect and president. Stephanie J. Lee, MD, MPH, will serve a four-year term as secretary. Jonathan D. Licht, MD, and Margaret A. Shipp, MD, will both serve four-year terms as councilors.
“Each of these individuals is extremely well-respected in our field and has already contributed a great deal to the Society,” said 2011 ASH President Armand Keating, MD, of Princess Margaret Hospital in Toronto. “I have every confidence in these newly elected Society leaders to further ASH’s commitment to move hematology forward during this very exciting time.”
David A. Williams, MD, is Chief of Hematology/Oncology and Director of Translational Research at Boston Children’s Hospital, Associate Chairman of the Department of Pediatric Oncology at Dana-Farber Cancer Institute, Leland Fikes Professor of Pediatrics at Harvard Medical School, and Director of the Pediatric Hematology/Oncology Fellowship Program at Boston Children’s Hospital and Dana-Farber Cancer Institute. Dr. Williams also serves as co-director of Boston Children's Hospital Fanconi Anemia/Bone Marrow Failure Multi-Disciplinary Clinic. His major fields of interest include molecular hematopoiesis and gene transfer into hematopoietic stem cells and the clinical care of children with hematologic diseases.
Stephanie J. Lee, MD, MPH, is a member of the Fred Hutchinson Cancer Research Center and Professor of Medical Oncology at the University of Washington School of Medicine in Seattle. She is an Attending Physician in the Hematopoietic Cell Transplantation Program at Fred Hutchinson and the Seattle Cancer Care Alliance. Her fields of interest include outcomes and health services research in hematologic malignancies and allogeneic hematopoietic cell transplantation, and late effects of hematopoietic cell transplantation, particularly chronic graft-versus-host disease.
Jonathan D. Licht, MD, is the Johanna Dobe Professor of Medicine and Chief of the Division of Hematology/Oncology at Northwestern University Feinberg School of Medicine in Chicago. He also serves as the Associate Director of Clinical Sciences at Northwestern’s Robert H. Lurie Comprehensive Cancer Center, where he is also an Attending Physician in the cancer center’s Leukemia Program. Dr. Licht’s areas of interest include epigenetics and aberrant gene expression in hematologic malignancies, including acute promyelocytic leukemia, large cell lymphoma, multiple myeloma, and myeloproliferative neoplasms.
Margaret A. Shipp, MD, is Professor of Medicine at Dana-Farber Cancer Institute and Harvard Medical School, Chief of the Division of Hematologic Neoplasia in the Department of Medical Oncology at Dana-Farber Cancer Institute, Director of the Lymphoma Program at Dana-Farber/Harvard Comprehensive Cancer Center, and Attending Physician in the Stem Cell Transplantation Program at Dana-Farber/Brigham and Women’s Cancer Center in Boston. Her major interest areas include clinical and molecular heterogeneity of large B-cell lymphomas and Hodgkin lymphoma, as well as the identification of unique lymphoma subtypes amenable to targeted therapy and mechanisms of immune evasion.
Reporters who wish to arrange an interview with a newly elected Executive Committee member may contact Andrea Slesinski, ASH Communications Manager, at 202-552-4927 or email@example.com.
American Society of Hematology
Boston Children's Hospital
The American Society of Hematology (www.hematology.org) is the world’s largest professional society concerned with the causes and treatment of blood disorders. Its mission is to further the understanding, diagnosis, treatment, and prevention of disorders affecting blood, bone marrow, and the immunologic, hemostatic, and vascular systems by promoting research, clinical care, education, training, and advocacy in hematology. The official journal of ASH is Blood (www.bloodjournal.org), the most cited peer-reviewed publication in the field, which is available weekly in print and online.